Joseph W Lubach

List of Publications by Year
in descending order

41	1,410	304743	330143
papers	citations	22 h-index	37 g-index

43	43	43	1928
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Magic angle spinning dynamic nuclear polarization solid-state NMR spectroscopy of Î³-irradiated molecular organic solids. Solid State Nuclear Magnetic Resonance, 2022, 119, 101785.	2.3	13
2	Attached Nitrogen Test by ¹³Câ€“¹⁴N Solid-State NMR Spectroscopy for the Structure Determination of Heterocyclic Isomers. Organic Letters, 2022, 24, 5635-5640.	4.6	2
3	Utilizing Solid-State Techniques and Accelerated Conditions to Understand Particle Size Instability in Inhaled Drug Substances. Journal of Pharmaceutical Sciences, 2021, 110, 3037-3046.	3.3	2
4	Effect of Counterions on Dissolution of Amorphous Solid Dispersions Studied by Surface Area Normalized Dissolution. Molecular Pharmaceutics, 2021, 18, 3429-3438.	4.6	3
5	Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity. ACS Medicinal Chemistry Letters, 2020, 11, 1588-1597.	2.8	12
6	Fast Acquisition of Protonâ€Detected HETCOR Solidâ€State NMR Spectra of Quadrupolar Nuclei and Rapid Measurement of NH Bond Lengths by Frequency Selective HMQC and RESPDOR Pulse Sequences. Chemistry - A European Journal, 2020, 26, 7881-7888.	3.3	28
7	Rapid Characterization of Formulated Pharmaceuticals Using Fast MAS ¹H Solid-State NMR Spectroscopy. Molecular Pharmaceutics, 2019, 16, 3121-3132.	4.6	32
8	Impact of Method of Preparation of Amorphous Solid Dispersions on Mechanical Properties: Comparison of Coprecipitation and Spray Drying. Journal of Pharmaceutical Sciences, 2019, 108, 870-879.	3.3	40
9	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Brutonâ€™s Tyrosine Kinase Inhibitor in Early Clinical Development. Journal of Medicinal Chemistry, 2018, 61, 2227-2245.	6.4	177
10	Solid-State NMR Investigation of Drug-Excipient Interactions and Phase Behavior in Indomethacin-Eudragit E Amorphous Solid Dispersions. Pharmaceutical Research, 2018, 35, 65.	3.5	24
11	Characterization of Pharmaceutical Cocrystals and Salts by Dynamic Nuclear Polarization-Enhanced Solid-State NMR Spectroscopy. Crystal Growth and Design, 2018, 18, 2588-2601.	3.0	54
12	In Situ Salt Formation during Melt Extrusion for Improved Chemical Stability and Dissolution Performance of a Meloxicamâ€“Copovidone Amorphous Solid Dispersion. Molecular Pharmaceutics, 2018, 15, 1226-1237.	4.6	20
13	Exploring Molecular Speciation and Crystallization Mechanism of Amorphous 2-Phenylamino Nicotinic Acid. Pharmaceutical Research, 2018, 35, 51.	3.5	6
14	In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound. Molecular Pharmaceutics, 2018, 15, 1607-1617.	4.6	11
15	Understanding Phase Behavior of Nearly Energetically Equivalent Polymorphs To Achieve Controlled Crystallization for a Nav1.7 Pain Inhibitor Compound. Molecular Pharmaceutics, 2018, 15, 5072-5080.	4.6	3
16	A rational approach towards development of amorphous solid dispersions: Experimental and computational techniques. International Journal of Pharmaceutics, 2017, 519, 44-57.	5.2	31
17	Characterization of the Particle Size and Polydispersity of Dicumarol Using Solid-State NMR Spectroscopy. Molecular Pharmaceutics, 2017, 14, 856-865.	4.6	20
18	Impact of Supramolecular Aggregation on the Crystallization Kinetics of Organic Compounds from the Supercooled Liquid State. Molecular Pharmaceutics, 2017, 14, 2126-2137.	4.6	10

#	Article	IF	Citations
19	Discovery of Potent and Selective Tricyclic Inhibitors of Brutonâ€™s Tyrosine Kinase with Improved Druglike Properties. ACS Medicinal Chemistry Letters, 2017, 8, 608-613.	2.8	26
20	Enhancing the resolution of¹H and¹³C solid-state NMR spectra by reduction of anisotropic bulk magnetic susceptibility broadening. Physical Chemistry Chemical Physics, 2017, 19, 28153-28162.	2.8	29
21	Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cellâ€“associated damage in IFNÎ±-driven lupus nephritis. JCI Insight, 2017, 2, e90111.	5.0	65
22	Interpolymer Complexation Between Polyox and Carbopol, and Its Effect on Drug Release From Matrix Tablets. Journal of Pharmaceutical Sciences, 2016, 105, 2386-2396.	3.3	9
23	Acid-base interactions in amorphous solid dispersions of lumefantrine prepared by spray-drying and hot-melt extrusion using X-ray photoelectron spectroscopy. International Journal of Pharmaceutics, 2016, 514, 456-464.	5.2	32
24	Probing the Distribution of Water in a Multi-Component System by Solid-State NMR Spectroscopy. Pharmaceutical Research, 2016, 33, 2470-2480.	3.5	1
25	Properties and mechanisms of drug release from matrix tablets containing poly(ethylene oxide) and poly(acrylic acid) as release retardants. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 105, 97-105.	4.3	17
26	Acidâ€“Base Interactions of Polystyrene Sulfonic Acid in Amorphous Solid Dispersions Using a Combined UV/FTIR/XPS/ssNMR Study. Molecular Pharmaceutics, 2016, 13, 483-492.	4.6	56
27	Discovery of highly potent and selective Brutonâ€™s tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 575-579.	2.2	34
28	Potent and selective Brutonâ€™s tyrosine kinase inhibitors: Discovery of GDC-0834. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1333-1337.	2.2	55
29	Investigation of Drugâ€“Excipient Interactions in Lapatinib Amorphous Solid Dispersions Using Solid-State NMR Spectroscopy. Molecular Pharmaceutics, 2015, 12, 857-866.	4.6	114
30	Solid-State Characterization of Novel Propylene Glycol Ester Solvates Isolated from Lipid Formulations. Molecular Pharmaceutics, 2015, 12, 2551-2557.	4.6	2
31	The Role of Lymphatic Transport on the Systemic Bioavailability of the Bcl-2 Protein Family Inhibitors Navitoclax (ABT-263) and ABT-199. Drug Metabolism and Disposition, 2014, 42, 207-212.	3.3	50
32	Characterization of a Waterâ€“Solid Interaction in a Partially Ordered System. Molecular Pharmaceutics, 2013, 10, 4294-4300.	4.6	9
33	Investigation of the Rat Model for Preclinical Evaluation of pH-Dependent Oral Absorption in Humans. Molecular Pharmaceutics, 2013, 10, 3997-4004.	4.6	25
34	Carbonâ€“Deuterium Rotational-Echo Double-Resonance NMR Spectroscopy of Lyophilized Aspartame Formulations. Journal of Pharmaceutical Sciences, 2012, 101, 283-290.	3.3	7
35	Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase Inhibitor. Drug Metabolism and Disposition, 2011, 39, 1840-1849.	3.3	69
36	Investigation of the Effects of Pharmaceutical Processing Upon Solid-State NMR Relaxation Times and Implications to Solid-State Formulation Stability. Journal of Pharmaceutical Sciences, 2007, 96, 777-787.	3.3	89

#	Article	IF	Citations
37	Multiple-sample probe for solid-state NMR studies of pharmaceuticals. Solid State Nuclear Magnetic Resonance, 2006, 29, 204-213.	2.3	31
38	Solid-state NMR Spectroscopy. , 2006, , 81-93.		4
39	Mechanochromism of Piroxicam Accompanied by Intermolecular Proton Transfer Probed by Spectroscopic Methods and Solid-Phase Changes. Journal of the American Chemical Society, 2005, 127, 6641-6651.	13.7	136
40	Effects of sucrose and mannitol on asparagine deamidation rates of model peptides in solution and in the solid state. Journal of Pharmaceutical Sciences, 2005, 94, 1723-1735.	3.3	18
41	Solid-state NMR studies of pharmaceutical solids in polymer matrices. Analytical and Bioanalytical Chemistry, 2004, 378, 1504-1510.	3.7	38